SECTOR OVERVIEW

Global Pharmaceuticals — Diabetes & Obesity Therapeutics (GLP-1)

Focus: NVO — Novo Nordisk A/S

2026-04-21

This report provides an overview of the global diabetes and obesity therapeutics sector, covering market sizing for GLP-1 receptor agonists, insulin, and adjacent metabolic categories; competitive dynamics dominated by the Novo Nordisk / Eli Lilly duopoly; the regulatory environment around compounding, pricing (IRA, Medicare negotiation), and label expansions; disruptive threat assessment including oral GLP-1s, triple agonists, amylin, and once-monthly administration; and Novo Nordisk's positioning following the 2024-2025 de-rating.

1. Market Size & Growth (TAM/SAM/SOM)

1.1 Global GLP-1 Therapeutics Market

The global GLP-1 receptor agonist (GLP-1 RA) market reached approximately US$74 billion in 2025, making it the largest therapeutic class in pharmaceutical history by revenue within a single decade of meaningful commercialization. Growth has been explosive — the market has expanded from US$22B in 2022 to US$74B in 2025 (CAGR +50%), driven by label expansion from Type 2 diabetes (T2D) into chronic weight management, cardiovascular risk reduction (MACE), obstructive sleep apnea (OSA), metabolic-associated steatohepatitis (MASH), and chronic kidney disease (CKD). Analyst consensus now projects the class to reach US$150-200B by 2030, representing a 15-20% CAGR from 2025.

The GLP-1 class is effectively a duopoly: Novo Nordisk (Ozempic, Wegovy, Rybelsus — all semaglutide) and Eli Lilly (Mounjaro, Zepbound — tirzepatide, a dual GIP/GLP-1 agonist) together control >95% of branded prescriptions. Volume-weighted share shifted materially through 2024-2025: NVO's share of new US branded GLP-1 prescriptions fell from ~55% in mid-2023 to ~42% by Q4 2025 as Zepbound's superior weight-loss efficacy in head-to-head data (SURMOUNT-5: 20.2% vs. 13.7%) translated into commercial momentum.

Source: IQVIA MIDAS, Airfinity, company filings, consensus estimates (Visible Alpha).

1.2 Broader Obesity & Metabolic Market

The total addressable obesity market is an order of magnitude larger than current prescription volume. The WHO estimates ~890 million adults live with obesity (BMI ≥30) and an additional ~1.6 billion are overweight (BMI 25-29.9). In the US alone, 42% of adults meet clinical obesity criteria. Against this population, current GLP-1 anti-obesity medication (AOM) patient count of ~9-10 million globally represents <2% penetration — the runway is structural, not cyclical. The bottleneck is access (payer coverage, supply, cost) rather than demand.

The broader diabetes care market reached US$110B in 2025, of which insulin accounts for ~US$26B (declining as GLP-1s substitute for basal insulin in T2D) and non-insulin antidiabetics US$84B (growing 18%, again driven by GLP-1s). NVO's Levemir discontinuation (US, Dec 2024) and overall insulin repositioning reflect the sector's strategic pivot from commoditizing insulin to higher-value incretins.

Source: IQVIA, Evaluate Pharma, GlobalData (2025 estimates).

1.3 TAM/SAM/SOM Framework

2. Key Growth Drivers and Headwinds

2.1 Growth Drivers

• Obesity label expansion: GLP-1s are transitioning from diabetes drugs into chronic disease management platforms. Wegovy carries a cardiovascular MACE reduction label (SELECT trial, 20% risk reduction) and is approved for OSA (SURMOUNT-OSA, 2024), MASH (ESSENCE, 2025), and CKD (FLOW, 2024). Each label expansion both grows the eligible population and improves payer coverage (e.g., MACE label opened Medicare Part D reimbursement).
• Penetration runway: Current AOM penetration <2% of the obese population globally. Even conservative adoption scenarios (10-15% penetration by 2035) imply US$250B+ class sales. Persistence rates are improving (60-65% one-year persistence vs. 35% in 2022) as supply stabilizes and patient education matures.
• Oral GLP-1 reformulations: NVO's oral semaglutide (Rybelsus) and next-generation oral amycretin/semaglutide combinations address the ~40% of eligible patients who decline injectables. Oral formulations are a key competitive lever where NVO has structural advantage through its SNAC absorption-enhancement platform (protected until 2031+).
• Pipeline diversification: NVO's pipeline extends beyond incretins — CagriSema (cagrilintide + semaglutide), amycretin (amylin/GLP-1 co-agonist), monlunabant (CB1 inverse agonist), and ziltivekimab (IL-6 for CVD in CKD/obesity). The rare disease franchise (Sogroya for growth disorders, Alhemo for hemophilia B inhibitor patients) provides diversification beyond metabolic.
• Catalent acquisition (closed Dec 2024, US$16.5B via Novo Holdings financing + NVO purchase of 3 fill-finish sites for US$11B): Removes the primary GLP-1 supply constraint. Wegovy supply normalized in Q2 2025 and incremental capacity is being added through 2027. Vertical integration into sterile fill-finish is a durable competitive moat against biosimilar GLP-1s (first biosimilar semaglutide not expected before 2033 given manufacturing complexity).
• Emerging market opportunity: China approved Wegovy (Jun 2024) and Mounjaro (May 2024) for obesity. EM diabetes prevalence is rising — China has 140M+ diabetics, India 100M+. NVO's geographic footprint (77 commercial markets) and lower-cost formulations (Rybelsus in tiered pricing) position it for secular EM volume growth.

2.2 Headwinds

• Tirzepatide efficacy lead: LLY's tirzepatide produces ~5-7 percentage points greater weight loss than semaglutide in head-to-head data (SURMOUNT-5 Dec 2024). Class-leading efficacy drives share gains, and LLY's follow-on retatrutide (triple agonist GLP-1/GIP/glucagon) showed 24% weight loss at 48 weeks (Phase 2) — potentially widening the efficacy gap further. NVO's response hinges on CagriSema and amycretin data over 2026-2027.
• CagriSema disappointment (Dec 2024): Phase 3 REDEFINE-1 showed 22.7% weight loss at 68 weeks (vs. 25% company target and buyside expectations >25%). The data was acceptable but not the leapfrog needed to reclaim efficacy leadership. REDEFINE-2 (T2D) reported Mar 2025 with 15.7% weight loss — again directionally positive but below expectations. These readouts removed the bull catalyst investors had priced in at the 2024 highs.
• Oral obesity pill readout (Jan 2025): Higher-dose oral semaglutide 25mg showed 13.6% weight loss at 64 weeks in OASIS-4, in line with subcutaneous 2.4mg. Market took the readout neutrally — efficacious but not differentiated enough to block LLY's orforglipron oral pill (Phase 3 readout expected 2H 2025).
• Pricing and IRA pressure: Medicare IRA negotiation added Ozempic/Rybelsus/Wegovy to the Medicare Part D negotiation list in January 2025, with maximum fair prices (MFP) effective 2027. Expected price concessions of 25-40% off list on negotiated volumes. Broader 340B and Medicaid pricing pressure continues. Net price erosion of ~3-5% annually for semaglutide franchise is now embedded in consensus.
• Compounded semaglutide: FDA removed Wegovy from its drug shortage list (Feb 2025), theoretically ending compounding pharmacy authority under 503A/503B exemptions. However, compounders continue selling via 'personalized' formulations and telehealth platforms (Hims, Ro, Henry Meds). Estimated 2-3 million US patients on compounded GLP-1s represent leakage from branded sales. Legal enforcement has been uneven.
• Supply normalization = pricing pressure: With Catalent integration bringing substantial incremental capacity online, the scarcity premium that insulated pricing in 2023-2024 is gone. Rebate pressure from PBMs and payer formulary exclusions has intensified in 2025, particularly in the commercial channel.

3. Competitive Landscape

3.1 Incretin / GLP-1 Duopoly

The GLP-1 class is a two-player race with NVO and LLY controlling >95% of branded sales. Other large pharma players are either out (Sanofi divested diabetes 2023), late (AstraZeneca's AZD5004 oral GLP-1 in Phase 2), or positioning through M&A (Roche acquired Carmot for CT-388 dual agonist). The cost, complexity, and efficacy bar for market entry are severe — any new incretin must beat tirzepatide's 20%+ weight loss to matter clinically.

Source: Company filings, EvaluatePharma, Clinicaltrials.gov (Apr 2026).

3.2 Broader Pharma Large-Cap Competitive Set

Beyond GLP-1, NVO competes with the large-cap pharma complex for investor capital. Large pharma's structural challenge in 2026-2030 is the 'patent cliff' — an estimated US$180B of revenue loss from LOE (loss of exclusivity) through 2030 across BMY (Revlimid, Eliquis), MRK (Keytruda LOE 2028), PFE (Eliquis, Ibrance), JNJ (Stelara biosimilars). NVO and LLY uniquely face the opposite problem: managing growth from dominant franchises. This asymmetric position drives the substantial valuation premium both names have historically traded at vs. the pharma group, though NVO's 2024-2025 de-rating has compressed that premium.

Source: Bloomberg, company filings, FactSet consensus (Apr 2026).

4. Regulatory Environment

4.1 US Drug Pricing: IRA & Medicare Negotiation

• Medicare IRA negotiation: CMS selected Ozempic, Rybelsus, and Wegovy (semaglutide) as part of the second cohort of Part D negotiated drugs in January 2025. Maximum Fair Prices (MFP) for this cohort become effective January 2027. Analyst consensus assumes ~30% net discount to pre-negotiation list, applied to negotiated eligible volume. Expected P&L impact: US$2.5-3.5B revenue headwind 2027-2028, partially offset by volume uplift from improved Part D formulary access.
• Part D redesign (effective Jan 2025): Restructured benefit shifts more cost to plans and manufacturers. OOP max $2,000/yr improves patient affordability (positive for volume) but manufacturer discount phase exposure increased from 50% to 10% of reach (brand-specific impact varies).
• Ongoing legislative pressure: Trump administration (2025-) has signaled willingness to pursue 'most-favored-nation' international reference pricing via executive action. Bipartisan support exists for capping GLP-1 out-of-pocket at $35/month (HHS Secretary statements Feb 2025). Direction of travel is clearly toward lower net prices over time.

4.2 Compounding & Supply Regulation

• FDA shortage list removal (Feb 2025): FDA resolved Wegovy's shortage designation, which technically removes 503B outsourcing facility authority to compound semaglutide. 503A (individual patient prescription) compounding remains available under personalization exemptions. NVO / LLY have filed suits against several telehealth compounders; outcomes mixed.
• Personalized compounding gray zone: Telehealth platforms (Hims, Ro, Noom, Henry Meds) continue to sell 'semaglutide combinations' (e.g., semaglutide + B12) arguing these qualify as personalized formulations. Estimated US$3-5B in compounded semaglutide sales in 2024 represents direct leakage from branded. FDA enforcement action is anticipated through 2026 but slow.
• State-level patient access mandates: NY, NJ, CA, MA have passed laws requiring payer coverage of AOMs for clinical obesity. This expands branded-drug access but does not address compounding. California SB 1290 specifically requires coverage of GLP-1 AOMs in Medicaid (Medi-Cal) effective 2026.

4.3 EU Regulatory & Reimbursement

• EMA: Semaglutide (Ozempic/Wegovy) approved across all EU indications. MASH (ESSENCE) approval expected 2H 2026. EU commercial model is tightly price-controlled through national HTA agencies (NICE in UK, G-BA in Germany, HAS in France) — GLP-1 pricing is 40-60% below US net levels.
• UK NICE: Wegovy is NHS-covered for BMI ≥35 with specific comorbidities, but service capacity constrains utilization. MASH label expansion will require separate NICE review.
• China NMPA: Wegovy approved June 2024. Ozempic has been in China since 2021 for diabetes. Tiered pricing (retail ~US$140/month, vs. US$1,350 US list) supports volume but caps margin contribution.

4.4 Advertising, Safety, & Misuse

• FDA DTC advertising guidance (Nov 2023): Mandates 'major statement' of risks in television ads in consumer-friendly language. Applies to both NVO and LLY GLP-1 campaigns; compliance cost modest.
• Gastric paralysis / suicidality signals: EMA conducted comprehensive safety review (concluded Apr 2024), found no causal link to suicidality; gastroparesis listed as 'known' risk. Ongoing real-world evidence generation required.
• Pediatric/adolescent authorization: Wegovy approved for pediatric obesity (age 12+) in US (2022) and EU (2023). AAP guidelines (2023) endorse AOM use in adolescents meeting clinical criteria, expanding addressable population by ~3M in US alone.

5. Sector KPIs and Benchmarks

5.1 Commercial & Franchise KPIs

Source: Company filings, Bloomberg, broker consensus (Apr 2026).

5.2 Valuation Benchmarks

NVO has de-rated from ~32x fwd P/E peak (Jun 2024) to 12.5x currently — now trading in line with pharma median despite superior growth and margins. Mean-reversion thesis depends on stabilizing GLP-1 share losses and delivering pipeline.

6. Disruptive Threat Assessment

Per coverage policy, disruptive/competitive technologies are evaluated for current scale, S-curve trajectory, trigger events, and NVO's positioning. No threat is dismissed without explicit justification.

6.1 Triple agonists (retatrutide / MariTide class)

• Current scale: Zero commercial revenue. Retatrutide (LLY) in Phase 3 (TRIUMPH program, obesity and T2D, readouts expected 2026-2027). MariTide (AMGN) Phase 2 ongoing with Phase 3 planned 2026.
• S-curve trajectory: Phase 2 retatrutide data showed 24.2% mean weight loss at 48 weeks — a ~5-7pp lead over tirzepatide, and ~10pp lead over semaglutide. If Phase 3 confirms efficacy with manageable tolerability, retatrutide becomes the class-leading therapy and reshapes share globally by 2028.
• Why it's a material threat: The efficacy delta is not marginal. In obesity, 25%+ weight loss crosses the threshold where surgical alternatives (bariatric surgery ~30%) become non-competitive. At that point, patient/prescriber preference will concentrate on the highest-efficacy option available.
• Trigger events that change the evaluation: (1) Retatrutide Phase 3 obesity readout (expected 2H 2026) — if efficacy holds ≥22%, NVO's share decline accelerates; if tolerability is problematic (GI adverse event discontinuation rates >15%), semaglutide/CagriSema remain competitive. (2) NVO's amycretin Phase 3 readout (2027) — amycretin Phase 1 showed 13.1% weight loss at 12 weeks, projecting to 22-25% at one year if the curve holds. A 25%+ result from amycretin neutralizes the retatrutide threat.
• NVO positioning: CagriSema (22.7% weight loss, REDEFINE-1) is the near-term defense. Amycretin (amylin/GLP-1 unimolecular co-agonist, Phase 2b) is the next-gen bet. If both underdeliver, NVO faces a structural efficacy gap through the end of the decade.

6.2 Oral small-molecule GLP-1s

• Current scale: Rybelsus (NVO's oral semaglutide, peptide-based) generates ~US$2.4B annually. LLY's orforglipron (oral small molecule) in Phase 3, readouts 2H 2025 / 1H 2026. Pfizer danuglipron discontinued 2024 due to AE profile; AZD5004 (AZN) and aleniglipron (Structure) in mid-stage.
• S-curve trajectory: Oral small molecules are structurally cheaper to manufacture than peptides (cost per dose could be 80-90% lower at scale, no sterile injection fill-finish requirement). If efficacy parity is demonstrated, the ~40% of patients who refuse injectables and a significant portion of the next-2-billion emerging-market opportunity could be addressed by oral only.
• Why it's a material threat: Manufacturing economics. If orforglipron demonstrates ≥15% weight loss at Phase 3 (Phase 2 showed 14.7% at 36 weeks), the cost structure enables pricing 50% below injectable semaglutide while preserving margin. This reshapes global access, particularly in emerging markets and primary care.
• Trigger events: (1) Orforglipron Phase 3 obesity efficacy ≥14% with adequate tolerability (Q4 2025 / Q1 2026). (2) NVO oral amycretin / oral CagriSema development progress. (3) Generic semaglutide filing timelines (2033+ for composition-of-matter; potentially earlier for specific-use patents).
• NVO positioning: Rybelsus + pipeline oral amycretin + SNAC absorption platform. Rybelsus high-dose OASIS-4 showed 13.6% weight loss — matches subcutaneous but launched too late with insufficient differentiation against orforglipron. NVO's oral platform remains commercially deployed; LLY is not yet at-market with oral.

6.3 Biosimilar / generic semaglutide

• Current scale: No approved biosimilars. Semaglutide composition-of-matter patent expires 2031 (EU) / 2032-2033 (US with pediatric extensions). Manufacturing complexity (peptide synthesis, SNAC formulation for oral) creates secondary barriers.
• S-curve trajectory: Biosimilar peptides have historically taken 3-5 years post-patent-expiry to achieve 40-60% price erosion, slower than small-molecule generic erosion. Semaglutide will likely follow insulin biosimilar precedent — gradual penetration, significant branded residual.
• Why it's manageable: Catalent acquisition locks up US fill-finish capacity. Pediatric/adolescent label extensions push regulatory exclusivity to 2033. Biosimilar developers (Teva, Biocon, Sandoz) have publicly indicated plans but no visible Phase 3 efficacy/bioequivalence studies yet.
• Trigger events: (1) First biosimilar semaglutide Phase 3 BE study initiation (monitor FDA/EMA listings). (2) Any successful patent challenge on formulation/SNAC claims. (3) Compounding reform that effectively legalizes generic peptide production pre-LOE.
• NVO positioning: Strong — Catalent integration, SNAC formulation patents (extending to 2036+), pipeline succession (CagriSema/amycretin) positioned to replace semaglutide revenue before LOE.

6.4 Amylin-class and amylin co-agonists

• Current scale: Pramlintide (Symlin, AstraZeneca) $150M annually, niche T1D use. Amylin-only obesity development largely NVO-controlled (cagrilintide, amycretin).
• S-curve trajectory: Amylin analogues address satiety via a different receptor system than GLP-1, enabling additive weight loss. If amycretin's dual action produces >25% weight loss at one year, it becomes the next-generation flagship.
• Why it's an opportunity (for NVO) rather than a threat: NVO has first-in-class positioning with cagrilintide and amycretin. Third parties (Zealand, Metsera) are mostly partnering into NVO/LLY rather than competing independently.
• Trigger events: Amycretin Phase 2b/3 data (2026-2027).

6.5 Weight-loss alternatives: bariatric surgery, endoscopic, device-based

• Current scale: US bariatric surgery ~256,000 procedures/year (flat 2020-2024 after modest decline due to GLP-1 substitution). Endoscopic sleeve gastroplasty ~15,000/yr. Intragastric balloons declining.
• S-curve trajectory: GLP-1s are substituting for bariatric procedures at the margin but have not collapsed surgery volumes (surgery retains durability advantages — weight regain with GLP-1 discontinuation is a known issue). Device-based interventions (Aspire, Intragastric) have been largely displaced.
• Why not a material threat: Direction of displacement is GLP-1 → surgery, not surgery → GLP-1. Even with maximal AOM adoption, there will be a surgical population for non-responders and severe obesity.
• Trigger events: Evidence of 'surgery renaissance' if GLP-1 weight-loss durability fails long-term (5-year + data). Monitor STEP-5 long-term extension data for maintenance failure rates.

6.6 Overall Disruption Conclusion

The most material disruptive threat to NVO is LLY's retatrutide / triple-agonist class. If retatrutide Phase 3 (2H 2026) confirms Phase 2 efficacy, NVO's share decline continues through 2028-2029 unless amycretin delivers comparable results. The oral small-molecule threat is real but bounded — NVO has competitive oral assets. Biosimilar and generic threats are distant (2032+). Alternative modalities are not displacing GLP-1 growth meaningfully.

Investment implication: The bull thesis for NVO requires (a) stabilization of share loss at 40-45% of class by 2027, (b) successful delivery of amycretin Phase 3 with ≥22% weight loss, (c) continuing MASH/CKD/OSA label expansion monetization. The bear thesis is retatrutide dominance + orforglipron commoditization of the rest of the market, with NVO caught in the middle.

7. Investment Implications

7.1 Bull Case for NVO

• De-rating overshoots fundamentals: Stock down ~72% from mid-2024 peak to $40 while revenue still grows low-double-digits, operating margin 44%, and franchise retains 40%+ share of fastest-growing drug class in history. 12.5x NTM P/E is below pharma median for an asset with NVO's growth profile.
• Amycretin and CagriSema optionality: Market ascribes minimal value to pipeline. Positive Phase 3 amycretin (2027) would represent a step-change in efficacy that could reclaim competitive positioning and re-rate multiples.
• Label expansion monetization: MASH (approval 2H 2026), CKD (FLOW label live 2025), OSA (SURMOUNT-OSA live) expand eligible population and improve payer coverage without additional drug development cost.
• Capital return: Catalent integration approaching completion; buyback program of DKK 20B announced Feb 2026. FCF inflection expected 2027 as Catalent capex tails off.

7.2 Bear Case for NVO

• Retatrutide commercialization + orforglipron launch in 2027-2028 pincers NVO from both premium (triple-agonist) and mass-market (oral small-molecule) ends of the market. Share loss re-accelerates.
• IRA pricing erosion + PBM rebate pressure compresses semaglutide franchise net price by 15-20% through 2028 without offsetting volume.
• Amycretin Phase 3 disappoints similar to CagriSema (below 25% target), removing the catalyst for re-rating.
• Compounded semaglutide leakage + generic threat post-2032 caps terminal value; DCF terminal multiple compresses to 9-10x EV/EBITDA.

7.3 Best Risk/Reward Setup

For an investor with 12-24 month horizon, NVO offers an attractive risk/reward at $40-45 given (a) the 70%+ drawdown has priced in substantial negative scenarios, (b) pipeline events are near-term and binary, (c) the underlying franchise is still growing. The key debate is not whether NVO is cheap — it demonstrably is vs. peers and vs. history — but whether the GLP-1 share loss stabilizes before retatrutide/orforglipron launches. Upside scenario: fair value US$55-60 on multiple re-rating to 16-18x P/E. Downside scenario: fair value US$30-34 if amycretin fails and share losses accelerate.

Paired trade consideration: Long NVO / Short LLY captures the valuation gap (NVO 12.5x vs. LLY 34x) with hedge against macro/class risk, though the efficacy spread argues for maintaining LLY long exposure separately.

8. Data Sources & Methodology

• Company filings: Novo Nordisk annual reports (2022-2024), interim reports (Q1-Q4 2025), investor day presentations (Mar 2024, Nov 2025).
• Clinical data: ClinicalTrials.gov (NCT identifiers for SURMOUNT, STEP, SELECT, REDEFINE, ESSENCE, FLOW programs), NEJM and Lancet published trial results.
• Market data: IQVIA MIDAS (global prescription volumes), Airfinity, EvaluatePharma, GlobalData, CDC obesity prevalence, WHO Global Health Observatory.
• Competitive benchmarks: Eli Lilly 10-K and 10-Q filings; AstraZeneca, Merck, Pfizer, Sanofi, AbbVie, Roche, GSK, BMY earnings releases.
• Regulatory: FDA press releases, CMS IRA negotiation communications, EMA assessment reports.
• Valuation: Bloomberg consensus, FactSet estimates, Visible Alpha (as of 2026-04-20).

DISCLAIMER: This report was produced by an agentic AI workflow (Agentic Finance Chile) for research and educational purposes. Data is current to Apr 2026 and may contain errors. Not investment advice. No position held by the author at time of publication.